News filter | Cheplapharm

View:
format_list_bulletedgrid_view

02/11/2022

CHEPLAPHARM announces successful pricing of Term Loan B

Investor Relations

Read morechevron_right

02/03/2021

CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents

Investor Relations

Read morechevron_right

01/26/2021

CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation

Investor Relations

Read morechevron_right

10/08/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of €575 Million 4.375% Senior Secured Notes due 2028 $500 Million 5.500% Senior Secured Notes due 2028

Investor Relations

Read morechevron_right

04/06/2020

CHEPLAPHARM - Quarterly Update Call Q4 / FY 2019

Cheplapharm Arzneimittel GmbH - Quarterly Update Call Q4 / FY 2019 | Wednesday, 08 April 2020, 10:30 BST | 11:30 CEST

Investor Relations

Read morechevron_right

01/29/2020

CHEPLAPHARM’s successful institutional bond debut: 500 million euros of senior secured notes at 3.500% placed with institutional investors

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding, following its last capital market transaction in May…

Investor Relations Archive Press releases

Read morechevron_right

01/28/2020

CHEPLAPHARM announces pricing of Senior Secured Notes

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of 100.0%.

Investor Relations Archive

Read morechevron_right